Replimune Group, Inc. - Common Stock (REPL)

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.